REGADENOSON

Post-LOE

regadenoson

Baxter

ANDAINTRAVENOUSSOLUTION

Approved

Apr 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

REGADENOSON (regadenoson) by Baxter is adenosine receptor agonists [moa]. Approved for adenosine receptor agonist [epc]. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

Adenosine Receptor Agonists

Pharmacologic Class:

Adenosine Receptor Agonist

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT06246188N/AUnknown

Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease

Started Jun 2025

80 enrolled

Coronary Artery Disease

NCT04604782Phase 1/2Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Started May 2021

54 enrolled

Myocardial IschemiaCoronary Artery Disease

NCT02130453Phase 4Completed

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Started Sep 2014

161 enrolled

Ischemia

NCT02220634N/ATerminated

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

Started Aug 2014

10 enrolled

Pulmonary Hypertension

NCT01788631Phase 2Completed

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Started Jul 2013

100 enrolled

Sickle Cell Anemia

Worked on REGADENOSON at Baxter? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.